LVK had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. LVK has been a consultant for Bristol-Myers Squibb, Eli Lilly & Co., Lundbeck, AstraZeneca, Pfizer, Wyeth, and Servier. However, none of the authors of this paper have any commercial associations that might pose a conflict of interest in connection with this manuscript.
Does lithium protect against dementia?
Version of Record online: 24 JAN 2010
© 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S
Volume 12, Issue 1, pages 87–94, February 2010
How to Cite
Kessing, L. V., Forman, J. L. and Andersen, P. K. (2010), Does lithium protect against dementia?. Bipolar Disorders, 12: 87–94. doi: 10.1111/j.1399-5618.2009.00788.x
- Issue online: 24 JAN 2010
- Version of Record online: 24 JAN 2010
- Received 14 May 2009, revised and accepted for publication 29 October 2009
- Alzheimer’s disease;
- bipolar disorder;
Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord 2010: 12: 87–94. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.
Objective: To investigate whether treatment with lithium in patients with mania or bipolar disorder is associated with a decreased rate of subsequent dementia.
Methods: Linkage of register data on prescribed lithium in all patients discharged from psychiatric health care service with a diagnosis of mania or bipolar disorder and subsequent diagnoses of dementia in Denmark during a period from 1995 to 2005.
Results: A total of 4,856 patients with a diagnosis of a manic or mixed episode or bipolar disorder at their first psychiatric contact were included in the study. Among these patients, 2,449 were exposed to lithium (50.4%), 1,781 to anticonvulsants (36.7%), 4,280 to antidepressants (88.1%), and 3,901 to antipsychotics (80.3%) during the study period. A total of 216 patients received a diagnosis of dementia during follow-up (103.6/10,000 person-years). During the period following the second prescription of lithium, the rate of dementia was decreased compared to the period following the first prescription. In contrast, the rates of dementia during multiple prescription periods with anticonvulsants, antidepressants, or antipsychotics, respectively, were not significantly decreased compared to the rate of dementia during the period with one prescription of these drugs.
Conclusions: Continued treatment with lithium was associated with a reduced rate of dementia in patients with bipolar disorder in contrast to continued treatment with anticonvulsants, antidepressants, or antipsychotics. Methodological reasons for these findings cannot be excluded due to the nonrandomized nature of the data.